AUTHOR=Zhang Chenyan , Zhang Pei , Cheng Ke , Cao Dan 

TITLE=Continuous response to maintenance fuzuloparib for germline BRCA2- mutated metastatic pancreatic adenocarcinoma: a case report and literature review

JOURNAL=Frontiers in Pharmacology

VOLUME=Volume 16 - 2025

YEAR=2025

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1656670

DOI=10.3389/fphar.2025.1656670

ISSN=1663-9812

ABSTRACT=Pancreatic adenocarcinoma with germline BRCA mutations (gBRCAm) represents a distinct molecular subtype with enhanced sensitivity to platinum-based chemotherapy and poly (ADP-ribose) polymerase inhibitors (PARP inhibitors). Fuzuloparib is a novel, potent, and orally bioavailable PARP inhibitor. Despite showing improved efficacy and a more favorable safety profile compared to olaparib in preclinical studies, clinical evidence for its application in pancreatic adenocarcinoma harboring gBRCAm remains limited. We report here a 33-year-old Asian woman with extensively metastatic pancreatic adenocarcinoma harboring a germline BRCA2 nonsense mutation who a durable response to fuzuloparib after NALIRIFOX chemotherapy. Her progression-free survival exceeded 15 months with ongoing fuzuloparib maintenance therapy for over 7 months. This case underscores the important role of biomarker-directed therapy in pancreatic adenocarcinoma and fuzuloparib may represent a potential PARP inhibitor option for maintenance treatment in pancreatic adenocarcinoma with gBRCAm. However, large-scale randomized controlled trials are needed to validate these results.